Abstract In this study, the effects of Radio Electric Asymmetric Conveyer (REAC), a non-invasive physical treatment, on neuroinflammatory responses in a mouse model of parkinsonism induced by intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were investigated in vivo. We found that the REAC tissue optimization treatment specific for neuro-regenerative purposes (REAC TO-RGN-N) attenuated the inflammatory picture evoked by MPTP-induced nigro-striatal damage in mice, decreasing the levels of pro-inflammatory molecules and increasing anti-inflammatory mediators. Besides, there was a significant reduction of both astrocyte and microglial activation in MPTP-treated mice exposed to REAC TO-RGN-N. These results indicated that REAC TO-RGN-N treatment modulates the pro-inflammatory responses and reduces neuronal damage in MPTP-induced parkinsonism.
Introduction
The innate immune response has been reported to be involved in the progression of several neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Creutzfeld-Jacob disease, HIV-associated dementia, stroke, and multiple sclerosis [1] [2] [3] [4] . In the healthy brain, microglia are responsible for active monitoring of the central nervous system environment, and are activated by any minor disturbance in the microenvironment, providing the first defense against injury and disease [5, 6] . In neuroinflammatory and neurodegenerative disorders, pro-inflammatory microglia become neurotoxic by secreting reactive oxygen species and cytokines in response to various environmental stimuli, causing neuronal injury and death if this response is prolonged. Microglia are involved in the inflammatory responses in the early stages of many neurodegenerative disorders [7, 8] . In particular, recent evidence has suggested that free radicals and oxidative stress play key roles in the pathogenesis of PD [9] . The widely-used methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD is characterized by substantial gliosis linked to activated Maria Antonietta Panaro, Alessandra Aloisi, and Giuseppe Nicolardi have contributed equally to this work. astroglia and microglia [10] . Inflammation has been shown to play an important role in MPTP-induced neurotoxicity [11, 12] . Many studies have demonstrated the beneficial effects of the Radio Electric Asymmetric Conveyer (REAC) in neuro-stimulation [13] [14] [15] [16] , regenerative medicine [17, 18] , cognitive disorders [19] [20] [21] [22] [23] [24] [25] , and AD [26] [27] [28] , as well as stem cell vitality during aging [29] .
The REAC technology combines low-intensity electromagnetic fields and electrical fields and is based on the production of a flow of micro-currents in the human body during treatment. The current flow can be focused, as required, on specific areas through an (asymmetric) single probe-conveyor, specific to REAC technology. In this study, we have utilized a specific treatment for neuroregenerative purposes (REAC TO-RGN-N) as previously described [28] .
It has been demonstrated that, in PC12 neuronal cells exposed to a REAC TO-RGN-N protocol, the number of cells committed toward the neurogenic phenotype is significantly increased as indicated by specific neurogenic genes, such as neurogenin-1, beta3-tubulin, nerve growth factor, and tyrosine hydroxylase, suggesting that REAC TO-RGN-N is able to up-regulate the expression of catecholaminergic phenotype genes [30, 31] .
The impact of REAC treatment has been demonstrated in a Tg2576 mouse model of AD, in which it modifies pathological neuroinflammation and mitigates part of the changes in complex motor behavior [28] .
In this study, we investigated the effect of this noninvasive physical treatment on microglial activation in a well-established MPTP mouse model of PD, and explored the modulation of neuroinflammatory responses by REAC.
Materials and Methods

Description of REAC Technology
REAC is a novel technology for bio-and neuro-modulation. REAC technology concentrates the micro-currents produced by ion fluxes through an asymmetric conveyer probe (ACP), in order to optimize the molecular mechanisms driving cellular asymmetry and polarization. The radio-electric fields interact with all structures that contain electrical charges, such as the human body, and induce currents in them. These currents vary according to the molecular characteristics of the tissues. The REAC technology generates a radio-electric field of very low intensity. The peculiarity of REAC technology is not the emission itself, but the particular physical link between the device and the patient's body. The ACP is this link. This is the innovation of REAC technology. REAC is an asymmetric technology, because there is only one single physical pole (asymmetrical circuit) instead of one positive and one negative (symmetrical circuit). This pole becomes the attractor (Asymmetric Conveyer) for the currents induced in the body by the radio-electric emission [14] [15] [16] [30] [31] [32] . The REAC technology is independent of the radio frequency emission used. REAC devices use only two frequencies (2.4 and 5.8 GHz), the most widely-used and permitted at the international level. Based on our clinical and scientific experience, 2.4 GHz was chosen because it better interacts with tissues, cell cultures, and the nervous system [13, 33, 34] .
The REAC protocol used in this study was tissue optimization regenerative treatment type N as previously described [28] . The REAC device was set for the REAC TO-RGN-N protocol in order to generate a 2.4 GHz radiofrequency emission of very low intensity (0.1 V/m at a distance of 3 m from the emitter), with on/off waveform modulation (750 ms on/1500 ms off). The ACP was the aluminum cage floor, while the stimulation points were the mouse paws. Postural position has no influence on the effects of REAC treatment, so there was no need to control mouse position during treatment [17] . The REAC TO-RGN-N was administered for 7 days without interruption. The REAC model device used in this study was B.E.N.E. (Bio-Enhancer Neuro-Enhancer, ASMED, Florence, Italy).
Animals and Treatments
Sixty adult male 129SV mice (22-26 g, 8-10 weeks of age) were purchased from Harlan (Correzzana, Italy) and housed under a 12-h light/12-h dark cycle in a climatecontrolled room with food and water ad libitum. All mouse experiments were performed following protocols approved by the Institutional Animal Committee and in accordance with EU Directive 2010/63/EU for animal experiments. All efforts were made to minimize animal suffering and to reduce the number of animals used. The treatment protocol details have been previously described [35, 36] . Briefly, a group of animals received four i.p. injections of the neurotoxin MPTP (20 mg/kg) (Sigma, Milan, Italy), in a total of four doses over an 8 h period and another group received sterile saline solution. Half of each group was daily subjected to REAC TO-RGN-N treatment starting from MPTP treatment day for 7 consecutive days, and were then sacrificed, since this is the optimal time for 80%-90% loss of dopamine in the striatum [35] .
Immunohistochemistry
Twenty animals (five for each experimental condition) were sacrificed by CO 2 inhalation at the end of the REAC TO-RGN-N treatment, 7 days after the MPTP or saline injection and then were perfused with 4% paraformaldehyde in 0.1 mol/L phosphate buffered saline (PBS) (pH 7.4). The brains were removed and placed in the same fixative for 1 h and transferred to 30% sucrose in 0.l mol/L PBS until they sank, then frozen. Brain sections (25 lm coronal sections) were cut on a cryomicrotome.
Immunohistochemistry was performed on free-floating sections following a standard avidin-biotin complex procedure. Briefly, the sections were incubated with 0.5% H 2 O 2 in 0.1 mol/L PBS for 1 h, followed by 3% bovine serum albumin in 0.1 mol/L PBS for 1 h, and overnight at 4°C with the mouse primary monoclonal antibodies antityrosine-hydroxylase (TH) clone 2/40/15 (1:1500; Millipore, Milan, Italy), anti-glial fibrillary acidic protein (GFAP) clone GA5 (Millipore; 1:1000), or anti-CD11b clone M1/70 (1:20; Developmental Studies Hybridoma Bank, Iowa City, IA), and then with an anti-mouse biotinylated secondary antibody (1:1000; Dako, Milan, Italy) for 1 h at room temperature and for 1 h with extravidin peroxidase (1:2000; Sigma, Milan, Italy). The immunocomplexes were visualized using 3,3
0 -diaminobenzidine/H 2 O 2 as chromogen.
Immunoblotting Assays
To obtain protein extracts, 20 mice were sacrificed by cervical dislocation 7 days after the last MPTP or saline injection, and the substantia nigra pars compacta (SNpc) was rapidly dissected according to Jackson-Lewis and Przedborski [35] . Sample preparation has been described by Panaro et al. [36] . Twenty-five micrograms of protein from each sample was size-fractionated on a denaturing, reducing 10% polyacrylamide minigel and electrophoretically transferred onto a nitrocellulose membrane.
Specific proteins were detected with optimal concentrations of the following specific antibodies: mouse anti-TH (Sigma-Aldrich), mouse anti-GFAP (Millipore), goat polyclonal antibody (pAb) anti-IL-1b (sc-1252), rabbit pAb anti-IL-1bRI (sc-25775), goat pAb anti-TNF-a (sc-1350), rabbit pAb anti-TNF-aRI (sc-7895), goat pAb anti-IL-6 (sc-1266), rabbit pAb anti-IL-6Ra (sc-660), rabbit anti-COX-2 (ab15191), rabbit anti-iNOS (sc-7271), goat pAb anti-SOCS-1 (sc-9021), rabbit anti-TLR4 (sc-10741) (Santa Cruz Biotechnology, Inc., Milan, Italy), and rabbit pAb anti-CD11b clone M1/70 (Abcam, Cambridge, UK). b-actin was used as a loading control. Membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and HRP-conjugated goat anti-mouse IgG (Bethyl Laboratories) for 60 min at room temperature in the dark on a shaker. Finally, bands were visualized by chemiluminescence (Bio-Rad, Milan, Italy), and subjected to densitometric analysis using ID image analysis software (Kodak Digital Science). The relative optical density was measured.
Real-Time PCR
The real-time PCR procedures have been described elsewhere [7] . Briefly, cDNA was amplified by real-time PCR where a target cDNA (GFAP, CD11b, IL-1b, IL-6, TNF-a, IL-1bRI, IL-6Ra and TNF-aRI, iNOS, TLR-4, COX-2, IL-10, SOCS-1, and TH) and a reference cDNA (glyceraldehyde-3-phosphate dehydrogenase, GAPDH) were amplified simultaneously using an oligonucleotide probe with a 5 0 fluorescent reporter dye (6-FAM) and a 3 0 quencher dye (NFQ). Fluorescence was determined on an ABI PRISM 7300-sequence detection system (Applied Biosystems, CA). Data were analyzed using the comparative threshold cycle (Ct) method and results are expressed as fold difference.
Statistical Analysis
All numerical data are expressed as the mean ± SD. Analysis of variance (ANOVA) was used to analyze all experimental data and the significance of the differences between results was determined by Scheffe's F-test as a post-hoc test. P \ 0.05 was considered to be statistically significant.
Results
Astroglial Activation
In the SNpc, GFAP immunoreactivity dramatically increased following MPTP treatment (Fig. 1A) , suggesting astrocyte activation. However, mice given MPTP and treated with the REAC TO-RGN-N protocol showed a less intense GFAP immunoreaction. Western blot analysis in SNpc lysates revealed that GFAP expression was augmented after MPTP administration, while REAC TO-RGN-N treatment caused a significant reduction of this protein in MPTP-treated mice. Mice exposed to REAC TO-RGN-N alone showed a GFAP expression level comparable to controls (Fig. 1B) . These data were further confirmed by GFAP mRNA expression analysis (Fig. 1C) .
Microglial Activation
CD11b was evaluated as a microglial marker in the SNpc of treated mice. The intensity of CD11b-immunoreactivity was augmented following MPTP administration in comparison to untreated animals. The increase of CD11b-immunoreactivity was reversed by REAC TO-RGN-N treatment. However, REAC TO-RGN-N treatment alone did not significantly alter CD11b-immunoreactivity relative to controls.
Immunoblotting analysis at the SNpc also showed a significant reduction of the CD11b level in MPTP-treated mice after exposure to REAC TO-RGN-N treatment (Fig. 2B ). Quantitative analysis of transcripts further confirmed that the CD11b mRNA level was significantly higher in MPTP-treated mice than in controls, whereas REAC TO-RGN-N exposure of MPTP-treated mice reduced the mRNA level (Fig. 2C) .
Analysis of Transcripts of Pro-inflammatory Cytokines
We also analyzed the expression of pro-inflammatory cytokines by quantitative RT-PCR. In the MPTP-treated mice, an increase of mRNA transcripts of IL-1b was detected (Fig. 3A) . Interestingly, we found that in MPTP mice exposed to REAC TO-RGN-N, IL-1b mRNA levels were significantly lower than in mice exposed to MPTP alone. No effects on the pro-inflammatory cytokine mRNA levels were detected in mice treated with REAC TO-RGN-N alone. Similar results were also obtained for IL-6 and TNF-a expression ( Fig. 3B and C) .
Analysis of Pro-inflammatory Cytokine Receptors
IL-1bRI, IL-6Ra, and TNF-aRI expression at the level of the SNpc was assayed by immunoblotting and quantitative RT-PCR (Fig. 4A, B and C, left) . Densitometric analysis of western blots revealed that REAC TO-RGN-N in MPTPtreated animals induced a significant reduction of proinflammatory cytokine receptors, in comparison to MPTPtreated mice not exposed to REAC TO-RGN-N. Quantitative analysis of mRNA transcripts (Fig. 4A, B and C, right) confirmed these results.
TLR-4, iNOS, and COX-2 Expression
We also analyzed the expression levels of other wellknown pro-inflammatory mediators, TLR-4, iNOS, and COX-2 in the SNpc by Western blotting and qRT-PCR. Results concerning the analysis of iNOS expression showed that in MPTP-treated mice, the levels of this protein were much higher than in untreated mice (Fig. 5A,  left) . REAC TO-RGN-N induced a significant reduction of iNOS in MPTP-treated mice relative to animals only given MPTP. These findings were confirmed by qPCR analysis (Fig. 5A, right) .
Results of the analysis of TLR-4 expression (Fig. 5B , left) evidenced that in MPTP-treated mice, the protein levels were much higher than in control animals. Meaningfully, the protein levels from densitometric analysis demonstrated that the amount of this receptor was significantly reduced in MPTP-treated mice after exposure to REAC TO-RGN-N in comparison to animals with MPTP alone. The qPCR analysis also confirmed these results for the TLR-4 mRNA levels (Fig. 5B, right) . Similar results were obtained for COX-2 expression (Fig. 5C , left and right).
IL-10 and SOCS-1 Analysis
In order to test a possible regulation of the anti-inflammatory responses in the brain of mice exposed to REAC TO-RGN-N, we analyzed the expression of the well-known anti-inflammatory cytokine IL-10 in the SNpc, in terms of mRNA expression by qRT-PCR analysis. MPTP treatment significantly increased the IL-10 mRNA level in comparison to control mice. However, a significant upregulation of IL-10 mRNA was detected in REAC TO-RGN-N-treated mice in comparison to MPTP-treated animals. More interestingly, combined REAC TO-RGN-N ? MPTP induced an additional increase of IL-10 mRNA expression in comparison to both MPTP alone and REAC TO-RGN-N alone (Fig. 6A) .
Suppressor of cytokine signaling (SOCS) proteins are among the possible modulators mediating feedback inhibition of cytokine-induced responses, acting as a negative regulator of cytokine signaling and able to suppress proinflammatory cytokine activity. Therefore, we tested the possible effect of REAC TO-RGN-N treatment on the expression of SOCS-1, one of the negative regulators of cytokine expression, in the brain of tested animals. Western blot analysis revealed a significant increase of SOCS-1 protein level in MPTP-treated animals in comparison to control. In mice exposed to REAC TO-RGN-N, SOCS-1 expression was up-regulated in comparison to MPTPtreated mice. Interestingly, also in mice exposed to REAC TO-RGN-N treatment with MPTP intoxication, the SOCS-1 level was significantly higher than in both untreated and MPTP-alone mice (Fig. 6B, left) . Accordingly, qRT-PCR analysis revealed that SOCS-1 mRNA was over-expressed in MPTP-treated mice exposed to REAC TO-RGN-N (Fig. 6B, right) .
Neuronal Damage
TH expression analysis was used to assess neurodegeneration (Fig. 7) . TH immunoreactivity decreased in both the caudateputamen (CP) and SNpc following MPTP administration (Fig. 7, panel A) . Besides, animals treated with REAC TO-RGN-N alone exhibited a TH immunoreactivity comparable to that in controls. Remarkably, TH immunostaining in MPTP-treated mice exposed to REAC TO-RGN-N was more intense than in animals that received neurotoxic treatment only. Western blot analysis of TH protein expression in SNpc lysates (Fig. 7B) showed that in the brain of animals treated with MPTP alone, TH expression was significantly lower than in controls. Interestingly, MPTP ? REAC TO-RGN-N treatment induced a significant increase of TH level in comparison to mice exposed to MPTP alone. No differences between REAC TO-RGN-N treatment and controls were found (Fig. 7B) .
Similarly, TH transcript expression significantly increased in animals exposed to MPTP ? REAC TO-RGN-N in comparison to animals given MPTP alone (Fig. 7C) .
Discussion
In this work we showed that REAC TO-RGN-N treatment is able to reduce pro-inflammatory responses in the brain of MPTP mice. In addition, REAC TO-RGN-N treatment was able to up-regulate the anti-inflammatory cytokine, IL-10, as well as SOCS-1 expression. These results strongly suggest the possibility that REAC TO-RGN-N treatment can have neuroprotective effects in MPTP-induced brain damage, reducing the amount of inflammatory mediators that are potentially neurotoxic and responsible for exacerbation of the neurodegenerative picture.
MPTP is a product of the chemical synthesis of a meperidine analog with potent heroin-like effects and induces parkinsonian features in humans, rodents, and nonhuman primates, causing rapid and selective dopaminergic (DA) neurotoxicity through oxidative mitochondrial damage, which results in neuronal death [37] . MPTP readily crosses the blood-brain barrier, and systemic administration produces lesions of the nigrostriatal DA pathway, leading to motor disorders including tremors, bradykinesia, abnormal postural reflexes, rigidity, and akinesia [38] . For these reasons, it is considered an excellent option in animal models for studies of pathogenesis, for testing neuroprotective therapies, and for assessing biomarkers to detect the disease pre-symptomatically [39] .
MPTP also leads to a sustained inflammatory response, probably linked to astroglial and microglial activation [40] . This is notably demonstrated when microglia are added to Values represent fold-changes relative to GAPDH and are expressed as mean ± SD (n = 5/group, 5 replicates; *P \ 0.05). A Left: densitometric analysis of IL-1bRI protein level in the control (C), MPTP, C-Reac, and MPTP-Reac groups (relative optical density after normalization against b-actin). Right: real-time PCR analysis of IL-1bRI mRNA expression levels in untreated (C), MPTP, C-Reac, and MPTP-Reac groups (fold change relative to GAPDH). B Left: densitometric analysis of IL-6R protein level in control (C), MPTP, C-Reac, and MPTP-Reac groups (relative optical density after normalization against b-actin). Right: real-time PCR analysis of IL-6R mRNA level in untreated (C), MPTP, C-Reac, and MPTP-Reac groups (fold-change relative to GAPDH). C Left: densitometric analysis of TNF-aRI protein level in control (C), MPTP, C-Reac, and MPTP-Reac groups (relative optical density after normalization against b-actin). Right: real-time PCR analysis of TNF-aRI mRNA expression in untreated (C), MPTP, C-Reac, and MPTP-Reac groups (fold-change relative to GAPDH). All values are expressed as mean ± SD (n = 5/group, 5 replicates; *P \ 0.05). neuronal cultures, leading to a greatly increased level of MPTP-induced DA toxicity [41] . Astroglia and microglia activation typical of neurodegenerative diseases leads to the chronic release of pro-inflammatory cytokines, such as IL-1b, TNF-a, and NO, which exacerbate the loss of DA neurons [42] [43] [44] .
In this respect, iNOS up-regulation, IL-1b, and IL-6 have already been demonstrated in the brain of MPTPtreated mice [45, 46] . Also, MPTP administration induces the expression of other cytokines involved in the process of inflammation including IL-10 and TNF-a [47] and their receptors [11] . In this work, we found that the levels of proinflammatory cytokines were significantly reduced by REAC TO-RGN-N in MPTP-induced parkinsonism. Apart from the reduction in cytokine expression, we also clearly demonstrated that REAC TO-RGN-N treatment in PD animals was able to significantly reduce the expression of other pro-inflammatory mediators, including iNOS and COX-2.
iNOS expression increases significantly in pathological conditions where robust gliosis is present. In fact, high levels of iNOS expression have been clearly demonstrated in many pharmacologically-induced parkinsonism models [48] . Once expressed, iNOS produces high levels of NO continuously from microglia or astrocytes [49, 50] . Other studies have also suggested that inhibition of iNOS is neuroprotective in the MPTP-induced PD model [51, 52] .
COX-2 is a pro-inflammatory enzyme that mediates the prostaglandin expression playing an important role in the etiology of PD [53] . Actually, it has been demonstrated that COX-2 is up-regulated in substantia nigra DA neurons in both PD patients and animal models, and that non-steroidal anti-inflammatory drug pre-treatment is able to protect against MPTP-or 6-hydroxy dopamine-induced nigrostriatal DA neuron degeneration [54] . Intriguingly, we found reduced levels of these pro-inflammatory molecules, both in terms of mRNA and protein, in REAC TO-RGN-Ntreated PD mice, thus suggesting the beneficial effects of REAC TO-RGN-N treatment in attenuating the pro-inflammatory responses.
IL-10 is a classic immunoregulatory and anti-inflammatory cytokine produced by activated microglia and is a potent inhibitor of inflammation. In fact, it has been shown to share a variety of immunomodulatory functions, including inhibiting the production of pro-inflammatory cytokines by microglia [55, 56] . It is notable that antiinflammatory cytokines, including IL-10, have been correlated with neuroprotection, recovery, and repair in various neurodegenerative diseases as well as in animal models of PD [57, 58] . We found that REAC TO-RGN-N was able to up-regulate IL-10 expression in mice exposed to MPTP, suggesting a possible modulatory effect of the inflammatory responses by activated microglia.
In the present study, we also suggest a possible mechanism involved in the protective action of REAC TO-RGN-N, by evaluating SOCS-1 expression in all tested animals. In this regard, we demonstrated SOCS upregulation, both in terms of mRNA transcripts and protein, in REAC TO-RGN-N treated mice. This result may also be correlated with the reduced expression of pro-inflammatory cytokines and their receptors, with the increased expression of the anti-inflammatory cytokine IL-10, as well as with the reduction of neuronal damage, in MPTP ? REAC TO-RGN-N-treated mice, while it was not detectable in mice exposed to MPTP alone.
In order to prevent uncontrolled inflammation in brain tissues, SOCS proteins play a key role, restricting cellular signaling pathways by enhancing the degradation of activated receptors and removing the stimuli for continued activation [59, 60] . Qin et al. reported that SOCS-1 expression induced by pro-inflammatory cytokines in astrocytes negatively regulates immune cell migration by reducing the expression of key chemokines [61] . Another study showed a decrease of SOCS-1 mRNA expression in peripheral blood leukocytes from multiple sclerosis patients [62] . Finally, in a transgenic model of AD, reduced levels of SOCS-1 have been correlated with enhanced neuroinflammation and neuropathology [63] .
The impact of REAC treatment has also been explored in other inflammation-based neurodegenerative diseases. In particular, it has recently been reported that REAC RGN-N treatment modifies pathological neuroinflammation and mitigates part of the changes in complex motor behavior observed in Tg2576 mice, an mouse model of AD [28] .
Overall, we showed an association between increased SOCS-1 expression and reduced pro-inflammatory responses in mice exposed to REAC TO-RGN-N.
Consistent with these results, we found that microglia activation, evaluated in terms of CD11b expression, in tissue sections after REAC TO-RGN-N treatment of MPTP-exposed animals, was significantly lower than in animals with MPTP only, thus suggesting a possible role for REAC TO-RGN-N treatment in modulating microglial activation. In the central nervous system, microglia play their physiological role by protecting neurons from invading microorganisms through a receptor of the innate immune system, TLR-4 [64] [65] [66] . Through the activated TLR4-dependent pathway, microglia produce NO and other pro-inflammatory mediators that, if produced at high levels, may cause neuronal degeneration [67] . Up-regulation of TLRs, including TLR-4, in the brain has been demonstrated in neurodegenerative conditions [12, 68] , indicating that innate immunity is a novel therapeutic target in these disorders. Also, MPTP toxicity is less severe in TLR4-deficient mice than in WT mice [10] .
Our results showed that in PD mice exposed to REAC TO-RGN-N there was a significant down-regulation of TLR-4 expression, suggesting involvement of the TLR-4-mediated signaling pathways in the inflammatory responses active in neurodegenerative diseases.
In summary, REAC TO-RGN-N exposure protects DA neurons against MPTP-induced neurotoxicity in mice by modulating the activation of astroglia and microglia. These effects were accompanied on the one hand by attenuated expression of pro-inflammatory factors and on the other hand by up-regulation of anti-inflammatory responses, as demonstrated by increased IL-10 mRNA and SOCS-1 upregulation. Further studies are needed to evaluate the potential application of REAC TO-RGN-N as therapeutic support in the treatment of neuroinflammatory diseases.
